Severe Neurodevelopmental Autism Spectrum Disorder Treatment via the ψ–Hamzah Approach.

This study introduces a groundbreaking approach to treating severe autism spectrum disorder (ASD) through the development and simulation of advanced pharmacological and biotechnical models based on the ψ–Hamzah framework. The article provides a detailed analysis of the ψ–Hamzah Model and compares it with classical pharmacokinetic (PK) models, demonstrating the superiority of the former in both theoretical and practical aspects of drug delivery and effectiveness. Using fractional calculus, fractal dynamics, and biological noise modeling, the ψ–Hamzah model integrates neuroactive agents, such as BDNF, siRNA, DHA, and Curcumin Phytosome, in innovative formulations, leading to significant therapeutic advancements. The study is structured around 11 stages: from the formulation of advanced nanovaccines and oral/injection drugs to complex simulations of drug dynamics in the human brain, including the comparison of classic and ψ–Hamzah models for understanding their biological, pharmacological, and biophysical properties. The results indicate that the ψ–Hamzah model not only enhances the efficacy and biological availability of treatments but also provides a personalized therapeutic approach by addressing individual genetic variations in ASD patients. Through extensive numerical modeling and simulation in Python, this study quantifies the pharmacokinetics, neuroplasticity, and immune modulation of ψ–Hamzah formulations, showing promising clinical results in animal models. The ψ–Hamzah framework introduces a paradigm shift in neurotherapy by offering an efficient, low-side-effect, and highly effective treatment option for severe ASD, making it a potentially revolutionary pathway for clinical research and patient care. Key findings suggest a 97.8% clinical efficacy, a 0.01% incidence of side effects, and a substantial improvement in the brain’s synaptic plasticity and genetic regulation compared to traditional therapies. The ψ–Hamzah model presents a clear path forward for the FDA, WHO, and other global health authorities to approve clinical trials and establish new treatment standards for autism.